April 8 (Reuters) - The U.S. Food and Drug Administration (FDA) declined to approve Supernus Pharmaceuticals' drug-device combination to treat movement-related symptoms of Parkinson's disease, the drugmaker said on Monday. (Reporting by Puyaan Singh in Bengaluru; Editing by Shinjini Ganguli)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
30.27 USD | +0.63% | +3.28% | +4.60% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
2,668 JPY | 0.00% | +0.45% | 9.06B | ||
160.8 USD | -0.56% | -3.87% | 286B | ||
30.27 USD | +0.63% | +3.28% | 1.65B | ||
0.85 USD | +0.24% | +54.55% | 529K | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.60% | 1.65B | |
+4.30% | 69.17B | |
+12.55% | 9.06B | |
-12.75% | 4.96B | |
+42.38% | 4.47B | |
+5.23% | 3.9B | |
+21.52% | 2.41B | |
-19.05% | 2.41B | |
-28.72% | 2.23B | |
+11.13% | 2.02B |
- Stock Market
- Equities
- SUPN Stock
- News Supernus Pharmaceuticals, Inc.
- U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease